Shots: Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders, focused on TNNI3-associated HCM & ARVC The acquisition will complement and […]readmore
Tags : Programs
Shots: Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program […]readmore
Shots: Reverie Labs to receive up front and is eligible to receive pre/clinical, regulatory milestones, as well as royalties on Roche’s sales of drug candidates, emerges from the collaboration Reverie […]readmore
Formycon signs an agreement with Bioeq AG and manufacturing partner for resubmission of BLA for FYB201 project (biosimilar, ranibizumab). Bioeq AG is in talks with the US FDA for resubmission […]readmore
Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in […]readmore
Shots: Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. Gilead acquires exclusive WW […]readmore
Shots: Axovant acquires WW development and commercialization rights for AXO-AAV-GM1 and AXO-AAV-GM2 Program and will make payments to University of Massachusetts The focus of the agreement is to develop functional copies of […]readmore